Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes

Diabetes, Obesity & Metabolism
J RosenstockA Hamann

Abstract

To assess the efficacy and tolerability of early combination therapy with rosiglitazone (RSG) and glimepiride (GLIM) vs. GLIM monotherapy in patients with type 2 diabetes mellitus (T2DM). Strategies for the addition of RSG in combination with GLIM were evaluated with data from two randomized, double-blind, placebo (PBO)-controlled studies. Study A - addition of RSG (4 or 8 mg) or PBO to continued GLIM 3 mg once daily; study B - addition of low-dose RSG (4 mg) prior to uptitration of GLIM (from 2 to 4 mg) vs. continued uptitration of GLIM (from 2 to 8 mg). Study A reported significant reductions in fasting plasma glucose (FPG) from baseline to week 26 with the addition of both 4 and 8 mg RSG to GLIM 3 mg [-21 mg/dl (-1.2 mmol/l), p = 0.0019 and -43 mg/dl (-2.4 mmol/l), p < 0.0001, respectively] and in haemoglobin A(1c) (HbA(1c)) (-0.63%, p = 0.00015 and -1.17%, p < 0.0001, respectively) from a baseline of 8.2 and 8.1%, respectively. At the end of the study, target HbA(1c) <7.0% was achieved in 43 and 68% of patients in the RSG 4 mg + GLIM and RSG 8 mg + GLIM groups, respectively, compared with 32% in the PBO + GLIM (GLIM alone) group. In study B, addition of RSG to GLIM reduced mean FPG and HbA(1c) levels at week 24 from baselin...Continue Reading

References

Feb 1, 1993·Annals of Internal Medicine·S StenmanL C Groop
Sep 1, 1996·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·D G Dills, J Schneider
Aug 1, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·K G Alberti, P Z Zimmet
Feb 26, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·B H WolffenbuttelR N Patwardhan
Feb 24, 2001·Diabetes Care·L S PhillipsUNKNOWN Rosiglitazone Clinical Trials Study Group
Mar 7, 2001·The Journal of Clinical Endocrinology and Metabolism·H E LebovitzUNKNOWN Rosiglitazone Clinical Trials Study Group
May 8, 2002·Diabetes/metabolism Research and Reviews·Francisco J Gómez-PerezErrol M Gould
Jul 24, 2002·Diabetologia·A LieblUNKNOWN ODE-2 Advisory Board
Oct 26, 2002·The American Journal of Cardiology·Martin I FreedUNKNOWN Rosiglitazone Study 108 investigators
Feb 7, 2003·Journal of Human Hypertension·G BakrisM I Freed
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Mar 6, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Jagdip S SidhuJuan Carlos Kaski
Jun 29, 2004·Diabetes Care·Jonathan B BrownAndrew Perry
Dec 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Stephen A SmithMartin I Freed
Dec 25, 2004·Diabetes Care·UNKNOWN American Diabetes Association
Jan 22, 2005·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·K G ParhoferB Göke
Oct 21, 2005·International Journal of Clinical Practice·S Del PratoUNKNOWN Global Partnership for Effective Diabetes Management
Apr 22, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Harold E LebovitzUNKNOWN ACE/AACE Diabetes Recommendations Implementation Writing Committee
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group

❮ Previous
Next ❯

Citations

Jun 18, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael BodmerChristoph R Meier
Feb 17, 2009·Diabetes/metabolism Research and Reviews

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.